AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20488274 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term awareness of hyperlipidemia
Number of subjects: 563
Study 18926131 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and exercise (1-hour cycling bout per day at 65%-70% of heart rate reserve)
Number of subjects: 26
Study 18926131 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation and exercise (800 mg calcium supplementation and 1-hour cycling bout per day at 65%-70% of heart rate reserve)
Number of subjects: 26
Study 18926131 — intervention group
Group type: COMPARATOR
Intervention: Placebo and no exercise
Number of subjects: 26
Study 17197376 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir/didanosine/lamivudine
Number of subjects: 12
Study 17197376 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir/didanosine/stavudine
Number of subjects: 12
Study 17197376 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz/lamivudine/zidovudine
Number of subjects: 12
Study 17197376 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 12
Study 12621132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg per day
Number of subjects: 635
Study 12621132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 10554512 — intervention group
Group type: EXPERIMENTAL
Intervention: Home i.v. treatment (HIT)
Number of subjects: 45
Study 10554512 — intervention group
Group type: COMPARATOR
Intervention: In-patient treatment (SIT)
Number of subjects: 45
Study 9772588 — intervention group
Group type: EXPERIMENTAL
Intervention: Beneficial Mixture for Body Immune Function (BMBIF)
Number of subjects: 20
Study 1928766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at a rate of 3 micrograms.kg‐1.min‐1 during surgery and the first postoperative 48 h
Number of subjects: 48
Study 1928766 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 48
Study 1928766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (after excluding patients receiving mannitol flush)
Number of subjects: 48
Study 1928766 — intervention group
Group type: COMPARATOR
Intervention: Saline (after excluding patients receiving mannitol flush, control group)
Number of subjects: 48
Study 1928766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dopamine and Saline)
Number of subjects: 48
Study 6350242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed schedule irradiation (two neutron and three photon fractions per week)
Number of subjects: 95
Study 6350242 — intervention group
Group type: COMPARATOR
Intervention: Standard photon irradiation
Number of subjects: 95
Study 29193247 — intervention group
Group type: EXPERIMENTAL
Intervention: Advair® 100/50
Number of subjects: 17
Study 29193247 — intervention group
Group type: EXPERIMENTAL
Intervention: Advair® 250/50
Number of subjects: 17
Study 29193247 — intervention group
Group type: EXPERIMENTAL
Intervention: Advair® 500/50
Number of subjects: 17
Study 27903009 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cold flow device (Hilotherm, Hilotherm GmbH, Germany)
Number of subjects: 50
Study 27903009 — intervention group
Group type: COMPARATOR
Intervention: Crushed ice packs (control group)
Number of subjects: 50
Study 26159147 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheel of Wellness counseling intervention (n=49)
Number of subjects: 93
Study 26159147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n=44)
Number of subjects: 93
Study 26159147 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheel of Wellness counseling intervention (n=43)
Number of subjects: 93
Study 26159147 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=46)
Number of subjects: 93
Study 23158114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 31
Study 23158114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21636098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.3mg
Number of subjects: 19
Study 21636098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1mg
Number of subjects: 19
Study 21636098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 3mg
Number of subjects: 19
Study 21636098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18281786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% with botulinum toxin A
Number of subjects: 16
Study 18281786 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with botulinum toxin A
Number of subjects: 16
Study 16928778 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time text (C-Print)
Number of subjects: 0
Study 16928778 — intervention group
Group type: COMPARATOR
Intervention: Sign language interpreting
Number of subjects: 0
Study 16928778 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time text (C-Print) and Communication Access Real-Time Translation
Number of subjects: 0
Study 16928778 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time text, direct (signed) instruction, and both
Number of subjects: 0
Study 16928778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpreting and interpreting plus real-time text
Number of subjects: 0
Study 12665986 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-frequency stimulation (CLFS) of knee extensor and hamstring muscles, 10 weeks, 4 hours per day, 7 days per week.
Number of subjects: 20
Study 12665986 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group, n=10) with no evoked contractions.
Number of subjects: 20
Study 11737046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) therapy
Number of subjects: 40
Study 11737046 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 40
Study 9264419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg twice daily
Number of subjects: 429
Study 9264419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin only
Number of subjects: 429
Study 9264419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 8509627 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (6 MU, thrice weekly)
Number of subjects: 234
Study 8509627 — intervention group
Group type: COMPARATOR
Intervention: Recombinant or natural interferon‐alpha (3 MU, thrice weekly)
Number of subjects: 234
Study 8509627 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month schedule of interferon administration
Number of subjects: 234
Study 8509627 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 234
Study 3540033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 156
Study 3540033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 156
Study 3540033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 156
Study 3540033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 156
Study 3540033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 29792885 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU intranasal vasopressin
Number of subjects: 25
Study 29792885 — intervention group
Group type: COMPARATOR
Intervention: Neutral control sounds
Number of subjects: 25
Study 27458307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus ipilimumab (10 mg/kg every 3 weeks for a total of four doses)
Number of subjects: 1132
Study 27458307 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 1132
Study 27458307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus ipilimumab (10 mg/kg)
Number of subjects: 1132
Study 27458307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus ipilimumab
Number of subjects: 1132
Study 24474619 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP‐E(+) group (ropivacaine with epinephrine)
Number of subjects: 52
Study 24474619 — intervention group
Group type: COMPARATOR
Intervention: TAP‐E(‐) group (ropivacaine without epinephrine)
Number of subjects: 52
Study 24474619 — intervention group
Group type: EXPERIMENTAL
Intervention: RSB‐E(+) group (ropivacaine with epinephrine)
Number of subjects: 52
Study 24474619 — intervention group
Group type: COMPARATOR
Intervention: RSB‐E(‐) group (ropivacaine without epinephrine)
Number of subjects: 52
Study 23430418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver
Number of subjects: 57
Study 23430418 — intervention group
Group type: COMPARATOR
Intervention: Cardiotomy suction system
Number of subjects: 57
Study 23430418 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 57
Study 21561371 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercise program (60 min, two times a week for 8 weeks)
Number of subjects: 38
Study 18287163 — intervention group
Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 1500 mg/d
Number of subjects: 4
Study 18287163 — intervention group
Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/d
Number of subjects: 4
Study 18287163 — intervention group
Group type: COMPARATOR
Intervention: Control (no pharmacologic or compression treatment)
Number of subjects: 4
Study 18287163 — intervention group
Group type: COMPARATOR
Intervention: Elastic compression stockings only
Number of subjects: 4
Study 16507350 — intervention group
Group type: EXPERIMENTAL
Intervention: Current atrial fibrillation (AF)
Number of subjects: 14703
Study 16507350 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior atrial fibrillation (AF)
Number of subjects: 14703
Study 16507350 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (AF)
Number of subjects: 14703
Study 14668173 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-digit couplings
Number of subjects: 100
Study 14668173 — intervention group
Group type: COMPARATOR
Intervention: Single digit couplings
Number of subjects: 100
Study 14668173 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 100
Study 14668173 — intervention group
Group type: COMPARATOR
Intervention: Three age groups (18 to 40+ years old)
Number of subjects: 100
Study 10956284 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 186
Study 10956284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 186
Study 10956284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8836663 — intervention group
Group type: EXPERIMENTAL
Intervention: MR889, 500 mg b.i.d. for 4 weeks
Number of subjects: 60
Study 8836663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8836663 — intervention group
Group type: EXPERIMENTAL
Intervention: MR889, 500 mg b.i.d. for 4 weeks (subset with short disease duration)
Number of subjects: 60
Study 1531426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (450 patients)
Number of subjects: 890
Study 1531426 — intervention group
Group type: COMPARATOR
Intervention: Control diet (440 patients)
Number of subjects: 890
Study 1531426 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet vs Control diet
Number of subjects: 890
Study 3896179 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysorbate 60
Number of subjects: 141
Study 3896179 — intervention group
Group type: COMPARATOR
Intervention: Glycerin (Control)
Number of subjects: 141
Study 3896179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-reported new hair growth
Number of subjects: 141
Study 3896179 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of new hair growth
Number of subjects: 141
Study 31880632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted spinal anesthesia
Number of subjects: 44
Study 31880632 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided spinal anesthesia
Number of subjects: 44
Study 29758153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2 dentifrice (Test)
Number of subjects: 0
Study 29758153 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate dentifrice (Control)
Number of subjects: 0
Study 29758153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 0
Study 27472565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary (IL) anesthesia
Number of subjects: 90
Study 27472565 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraperiosteal (SP) anesthesia
Number of subjects: 90
Study 27472565 — intervention group
Group type: EXPERIMENTAL
Intervention: CCDS-administered IL anesthesia
Number of subjects: 90
Study 25410083 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (manipulation) with supervised exercise regime
Number of subjects: 62
Study 25410083 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise regime alone
Number of subjects: 62
Study 22412149 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based tailored education program for CRF, 12 weeks duration
Number of subjects: 273
Study 22412149 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 273
Study 19878101 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of 20% albumin
Number of subjects: 6
Study 19878101 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of Ringer's acetate solution
Number of subjects: 6
Study 18560227 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 42
Study 18560227 — intervention group
Group type: EXPERIMENTAL
Intervention: amodiaquine-sulfalene-pyrimethamine
Number of subjects: 42
Study 16332471 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Child Health Doctors (CHDs) in a structured method to identify psychosocial problems
Number of subjects: 6375
Study 16332471 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 6375
Study 12564609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet (500 microg three times daily) plus placebo (twice daily)
Number of subjects: 0
Study 12564609 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily) plus placebo (three times daily)
Number of subjects: 0
Study 12564609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily) plus a second placebo (three times daily)
Number of subjects: 0
Study 11236240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with type 2 diabetes
Number of subjects: 40
Study 8628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) therapy, 10 mg/kg IV followed by 100 mg orally daily until delivery.
Number of subjects: 110
Study 1458895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical dilator (Lamicel; n = 17)
Number of subjects: 64
Study 1458895 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (gemeprost; n = 17)
Number of subjects: 64
Study 1458895 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiprogesterone (Mifepristone; n = 15)
Number of subjects: 64
Study 1458895 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (n = 15)
Number of subjects: 64
Study 6142007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg)
Number of subjects: 10
Study 6142007 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 10
Study 6142007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30930211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Recruitment Maneuver (PRM) with maximal inspiratory pressure of 30 cm H2O
Number of subjects: 84
Study 30930211 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 31039878 — intervention group
Group type: EXPERIMENTAL
Intervention: GO/Cu₂O composite
Number of subjects: 0
Study 27943408 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 99
Study 27943408 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetics)
Number of subjects: 99
Study 25196976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (doses ranging from 500 to 3000 mg)
Number of subjects: 376
Study 25196976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 376
Study 22451196 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3 mg)
Number of subjects: 20
Study 22451196 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (10 mg)
Number of subjects: 20
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) in women
Number of subjects: 120852
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) in men
Number of subjects: 120852
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Former cigarette smoking
Number of subjects: 120852
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cigarette smoking
Number of subjects: 120852
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking duration
Number of subjects: 120852
Study 21173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (per 10 g ethanol/d)
Number of subjects: 120852
Study 19292213 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital group
Number of subjects: 88
Study 19292213 — intervention group
Group type: COMPARATOR
Intervention: Acquired group
Number of subjects: 88
Study 16485700 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting (LD) filter
Number of subjects: 60
Study 16485700 — intervention group
Group type: COMPARATOR
Intervention: Control standard arterial line filter
Number of subjects: 60
Study 14585882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of IUD position immediately after insertion
Number of subjects: 195
Study 14585882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of IUD position at follow-up (6 weeks after insertion)
Number of subjects: 195
Study 11124286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 5-fluorouracil (3 subconjunctival injections of 5 mg each over 11 postoperative days)
Number of subjects: 40
Study 11124286 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without 5-fluorouracil
Number of subjects: 40
Study 9020998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (5 micrograms kg‐1 min‐1)
Number of subjects: 45
Study 9020998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1364168 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 7
Study 1364168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 7
Study 1364168 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine
Number of subjects: 7
Study 1364168 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 7
Study 1364168 — intervention group
Group type: COMPARATOR
Intervention: All antihistamines
Number of subjects: 7
Study 3974097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral albuterol, 4 mg
Number of subjects: 20
Study 3974097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate, 20 mg
Number of subjects: 20
Study 3974097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline sulfate, 5 mg
Number of subjects: 20
Study 30509278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP definition patterns (8 patterns identified)
Number of subjects: 319
Study 26406192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrax group (TG) - 15 minutes exercise session 3 times weekly for 4 weeks
Number of subjects: 57
Study 26406192 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation group (EG) - 40 minutes electrostimulation of postural muscles 3 times weekly for 4 weeks
Number of subjects: 57
Study 26406192 — intervention group
Group type: COMPARATOR
Intervention: Control group - 6-week balance exercises
Number of subjects: 57
Study 26420180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg of vitamin B‐12
Number of subjects: 30
Study 26420180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g fish oil
Number of subjects: 30
Study 26420180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg vitamin B‐12 and 2 g fish oil
Number of subjects: 30
Study 23423495 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (GIH A)
Number of subjects: 103
Study 23423495 — intervention group
Group type: COMPARATOR
Intervention: No feedback (GIH B, control group)
Number of subjects: 103
Study 23423495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 21906811 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-403 (0.3 to 5.0 mg/kg)
Number of subjects: 16
Study 21906811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18362604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mm
Number of subjects: 0
Study 18362604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mm
Number of subjects: 0
Study 18362604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 100 mm
Number of subjects: 0
Study 18362604 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 18362604 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine‐prilocaine cream (positive control)
Number of subjects: 0
Study 18362604 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (all concentrations)
Number of subjects: 0
Study 16980157 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-diclofenac
Number of subjects: 90
Study 16980157 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-placebo
Number of subjects: 90
Study 16980157 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo-diclofenac
Number of subjects: 90
Study 12356389 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 28
Study 12356389 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) + L-arginine
Number of subjects: 28
Study 12356389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10332518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsoft Natural Keyboard (kb3)
Number of subjects: 80